Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on May 31, 2023. The filing discloses significant changes in executive leadership and board composition effective June 2, 2023, in preparation for a pending merger with Infinity Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Executive Transition: The Board terminated the employment of Daniel Gold, Ph.D., as President and CEO, effective June 2, 2023. Simultaneously, David M. Urso was appointed President and CEO, effective the same date.
- Board Expansion: The Board size increased from 7 to 8 directors as of June 8, 2023, with Mr. Urso elected as a new member.
- Merger Context: These changes align with a previously disclosed Merger Agreement (dated February 22, 2023) to merge with Infinity Pharmaceuticals, Inc., where Mr. Urso was designated to serve as CEO upon the merger's effective date.
Guidance, Outlook, and Compensation Details
Outlook and Strategy: The leadership transition is intended to provide an orderly transition of duties prior to the consummation of the merger with Infinity Pharmaceuticals.
Compensation Arrangements:
- David Urso (New CEO):
- Annual base salary: $614,000.
- Target annual bonus: 50% of base salary.
- Equity: Granted an option to purchase 2.5% of outstanding shares (CEO Initial Grant) vesting over 4 years. A second grant (CEO Second Grant) of up to 2.5% of outstanding shares is contingent on the merger closing, subject to a 200,000-share annual limit.
- Severance: 12 months of base salary and accelerated vesting of 12 months of options upon termination without cause or resignation for good reason.
- Daniel Gold (Outgoing CEO):
- Termination classified as "without cause."
- Severance: 12 months of base salary, accelerated vesting of options for the next 12 months, and a discretionary annual bonus for the fiscal year ending June 30, 2023.
- Mr. Gold remains a member of the Board.
Investor Verification Checklist
- Verify the status and expected closing date of the merger with Infinity Pharmaceuticals, Inc.
- Review the full text of the CEO Employment Agreement (Exhibit 10.1) for specific vesting schedules and change-in-control provisions.
- Confirm the impact of the 200,000-share annual equity limit on the "CEO Second Grant" and potential "Top Off Grant" in 2024.
- Assess the financial implications of the severance packages for both the outgoing and incoming CEOs.
- Monitor the company's cash position to ensure it can fund the new CEO's salary and potential severance obligations.